Compare USBC & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USBC | DERM |
|---|---|---|
| Founded | N/A | 2014 |
| Country | | United States |
| Employees | 24 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.4M | 210.0M |
| IPO Year | N/A | 2021 |
| Metric | USBC | DERM |
|---|---|---|
| Price | $0.57 | $8.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | N/A | ★ 129.3K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $59,399,000.00 |
| Revenue This Year | N/A | $17.48 |
| Revenue Next Year | N/A | $55.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.82 |
| 52 Week Low | N/A | $3.54 |
| 52 Week High | N/A | $9.40 |
| Indicator | USBC | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 34.31 | 53.99 |
| Support Level | $0.57 | $7.15 |
| Resistance Level | $0.61 | $8.40 |
| Average True Range (ATR) | 0.04 | 0.41 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 11.25 | 72.03 |
USBC Inc is a multi-disciplinary technology company that is an innovator in digital financial technologies. The company develops financial services including digital assets and banking solutions, as well as non-invasive health monitoring research. USBC has implemented a Bitcoin treasury strategy to support development and research across its various divisions. A key focus is the further development of its tokenized deposit program, a tokenized representation of a U.S.-dollar-denominated bank deposit account that operates on blockchain technology and is embedded with digital identity, alongside its legacy non-invasive sensor technology business, with the objective of creating long-term shareholder value in an evolving financial landscape.
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.